Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
Frontiers in Neurology2020Vol. 11, pp. 1053–1053
Citations Over TimeTop 10% of 2020 papers
Antônio Edvan Camelo-Filho, André Macedo Serafim da Silva, Eduardo de Paula Estephan, Antônio Alberto Zambon, Rodrigo de Holanda Mendonça, Paulo Victor Sgobbi de Souza, Wladimir Bocca Vieira de Rezende Pinto, Acary Souza Bullé Oliveira, Iron Dangoni-Filho, Ana Flávia Pincerno Pouza, Berenice Cataldo Oliveira Valério, Edmar Zanoteli
Abstract
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
Related Papers
- → Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor(2008)29 cited
- → Investigation of the Relationship Between Oral Lesions and Early Pneumonia Associated with Mechanical Ventilation in Patients Undergoing Mechanical Ventilation in Intensive Care Unit(2016)1 cited
- → Factors associated with survival in patients undergoing invasive mechanical ventilation in an intensive care unit in Colombia v1(2020)1 cited
- → The Effect of Co-Morbid Diseases on The Need for Mechanical Ventilation and Mortality of Patients with Covid-19 in Intensive Care Unit(2021)1 cited